###begin article-title 0
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Effect of statin therapy on serum activity of proteinases and cytokines in patients with abdominal aortic aneurysm
###end article-title 0
###begin title 1
Background and aims:
###end title 1
###begin p 2
###xml 162 169 <span type="species:ncbi:9606">patient</span>
Metalloproteinases (MMPs) are considered to be key enzymes in the pathogenesis of abdominal aortic aneurysms (AAA), with elevated levels in diseased aorta and in patient sera. Statins seem to exert an inhibitory effect on MMP activity in the aortic wall. No data exist on the effect of statins on serum activity of MMPs and inflammatory cytokines (interleukins, IL).
###end p 2
###begin title 3
Methods:
###end title 3
###begin p 4
###xml 85 93 <span type="species:ncbi:9606">patients</span>
The serum activities of MMP2 and MMP9, osteoprotegerin (OPG), and IL6 and IL10 in 63 patients undergoing elective infrarenal aneurysm repair were measured on the day before surgery. Levels were correlated to statin therapy and aneurysm diameter.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
There was no significant difference between the two groups in the activity of circulating levels of MMP2/9, OPG, and IL6/10 in patients with infrarenal aortic aneurysm. IL6 levels in patients with AAA larger than 6 cm were significantly elevated; differences in serum activities of MMP2/9, OPG, and IL10 were not related to AAA diameter.
###end p 6
###begin title 7
Conclusion:
###end title 7
###begin p 8
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Serum activities of MMP2/9, OPG, and IL6/10 are not correlated to statin therapy; IL6 levels are higher in patients with large aneurysms. Hence the effect of statin therapy in the treatment of aneurismal disease remains to be elucidated.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 404 423 404 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-vhrm-4-1433">Tamarina at al 1997</xref>
###xml 425 445 425 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-4-1433">Hovsepian et al 2000</xref>
###xml 447 466 447 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-vhrm-4-1433">Lindholt et al 2000</xref>
###xml 468 485 468 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-vhrm-4-1433">Annabi et al 2002</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
Metalloproteinases (MMPs) are believed to play a key role in the development of aneurismal disease of the aorta, although the precise mechanisms leading to aneurysm formation remain unclear. Elevated levels of MMP2 and MMP9 have been shown in the extract tissue from surgical specimens and in the sera of patients with aortic aneurysm, compared with nondiseased aorta and healthy controls, respectively (Tamarina at al 1997; Hovsepian et al 2000; Lindholt et al 2000; Annabi et al 2002).
###end p 10
###begin p 11
###xml 208 225 208 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-vhrm-4-1433">Dawson et al 2007</xref>
###xml 437 453 437 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-4-1433">Evans et al 2007</xref>
###xml 536 562 536 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-4-1433">Kalyanasundaram et al 2006</xref>
###xml 721 737 721 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-4-1433">Diehm et al 2007</xref>
###xml 872 890 872 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-vhrm-4-1433">Tziakas et al 2004</xref>
###xml 1228 1244 1228 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-vhrm-4-1433">Moran et al 2005</xref>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 530 534 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 833 841 <span type="species:ncbi:9606">patients</span>
###xml 1011 1019 <span type="species:ncbi:9606">patients</span>
###xml 1268 1276 <span type="species:ncbi:9606">patients</span>
A common feature of vascular disease and aneurysm formation is an inflammatory process in the aneurismal wall with invasion of monocytes and macrophages and increased levels of interleukins (IL) such as IL6 (Dawson et al 2007). Hence one therapeutic approach in the conservative management of patients with aortic aneurysm aims to inhibit this inflammation and matrix turnover by statins and angiotensin II inhibitors (Abisi et al 2007; Evans et al 2007). Simvastatin has been shown to suppress experimental aneurysm formation in rats (Kalyanasundaram et al 2006). Currently, the cessation of smoking, and antiplatelet and statin therapy are recommended in conservative treatment of patients with small aortic aneurysms (Diehm et al 2007; Golledge et al 2007). Statin treatment has been shown to reduce circulating levels of MMPs in patients with acute coronary syndrome (Tziakas et al 2004). However, no data are available on the effect of statins on circulating levels of representative MMPs and cytokines in patients with abdominal aortic aneurysm (AAA). Hence we studied the serum activity of MMP2/9, osteoprotegerin (OPG) - a recently identified promoter of vascular disease that has been correlated to aneurysm expansion (Moran et al 2005) - and IL6 and IL10 in patients undergoing elective infrarenal aortic aneurysm repair and correlated the measurements to statin therapy and aneurysm diameter.
###end p 11
###begin title 12
Methods
###end title 12
###begin p 13
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
The study was approved by the local ethics committee and informed consent was obtained from all patients preoperatively. Sixty-three patients undergoing elective infarenal aneurysm repair were recruited for this study; 25 patients were on regular statin therapy before surgery. Statin therapy lasted for at least 4 weeks before surgery; 23 patients were on simvastatin at a dose of 10-40 mg once daily, and 2 patients were on fluvastatin 80 mg once daily. All subjects had their surgical procedure at the Department of Thoracic and Vascular Surgery, University of Ulm, between 2005 and 2007. Blood samples were taken 1 day before surgery, immediately centrifuged for 10 min at 4000 rpm, and stored at -80 degreesC until measurements.
###end p 13
###begin title 14
Matrix metalloproteinase activity bioimmunoassay
###end title 14
###begin p 15
Active forms of MMP2 and MMP9 were measured using specific quantitative activity bioimmunoassays (Chemicon) according to the manufacturer's instructions. MMP2 and MMP9 activity was expressed in nanograms per milliliter.
###end p 15
###begin title 16
Osteoprotegerin
###end title 16
###begin p 17
OPG activity was measured using a commercially available Enzyme Linked Immuno Sorbent Assay (BioCat) according to the manufacturer's instructions. OPG activity was expressed in picograms per milliliter.
###end p 17
###begin title 18
Interleukin 6 and 10
###end title 18
###begin p 19
Levels of IL6 and IL10 were determined using a Enzyme Linked Immuno Sorbent Assay (R&D Systems). The manufacturer's instructions were followed throughout.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
For discrete variables, absolute and relative frequencies are given. For continuous frequencies, median values and range are applied as they were not normally distributed. To calculate the significance of difference in activity between the treatment groups the Mann Whitney U test was used. To calculate the significance of the relationship between AAA diameter and serum activity the Kruskal-Wallis one way analysis of variance on ranks was applied. P values <0.05 were regarded as significant. Statistical analysis was performed in collaboration with the Department of Biometry using the computer program SigmaStat.
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient data
###end title 23
###begin p 24
###xml 103 110 103 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-vhrm-4-1433">Table 1</xref>
###xml 8 15 <span type="species:ncbi:9606">patient</span>
The two patient groups were comparable for age, aneurysm diameter, sex, and pre-existing risk factors (Table 1).
###end p 24
###begin title 25
Biomarker activity as a function of statin therapy
###end title 25
###begin p 26
###xml 411 420 411 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-vhrm-4-1433">Figures 1</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5-vhrm-4-1433">5</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
There was no statistically significant difference in the serum activity of MMP2/9, OPG, and IL6/10 in patients with or without statin therapy: median values for MMP2 activity were 209 vs 211 ng/mL respectively, and for MMP9 activity 38 vs 37 ng/mL, respectively. OPG values were 417 vs 430 pg/mL, respectively. IL6 and IL10 levels also did not differ significantly: 5 vs 7 pg/mL and 6 vs 5 pg/mL, respectively (Figures 1-5).
###end p 26
###begin title 27
Biomarker activity as a function of AAA diameter
###end title 27
###begin p 28
###xml 336 343 334 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-4-1433">Table 2</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
To test the correlation of biomarker activity and AAA diameter, patients were divided into 3 groups: AAA diameter </=5 cm, 5.1-6.0 cm, >6.0 cm. Using this separation there was no difference in the serum activity of MMP2, MMP9, OPG, and IL10; aneurysms >6 cm in diameter showed significantly higher levels of IL6 than smaller aneurysms (Table 2).
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 385 401 385 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-4-1433">Diehm et al 2007</xref>
###xml 582 601 582 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-vhrm-4-1433">Schouten et al 2006</xref>
###xml 603 619 603 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-4-1433">Evans et al 2007</xref>
###xml 757 776 757 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-vhrm-4-1433">Golledge et al 2006</xref>
###xml 1064 1084 1064 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-vhrm-4-1433">Tousoulis et al 2006</xref>
###xml 2232 2249 2232 2249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-vhrm-4-1433">Dawson et al 2007</xref>
###xml 2409 2428 2409 2428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-vhrm-4-1433">Petersen et al 2002</xref>
###xml 2585 2609 2585 2609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-vhrm-4-1433">McMillan and Pearce 1999</xref>
###xml 2611 2631 2611 2631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-4-1433">Hovsepian et al 2000</xref>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 839 847 <span type="species:ncbi:9606">patients</span>
###xml 914 922 <span type="species:ncbi:9606">patients</span>
###xml 959 967 <span type="species:ncbi:9606">patients</span>
###xml 1090 1098 <span type="species:ncbi:9606">patients</span>
###xml 1274 1282 <span type="species:ncbi:9606">patients</span>
###xml 1577 1585 <span type="species:ncbi:9606">patients</span>
###xml 1629 1637 <span type="species:ncbi:9606">patients</span>
###xml 1784 1792 <span type="species:ncbi:9606">patients</span>
###xml 1888 1896 <span type="species:ncbi:9606">patients</span>
###xml 1939 1947 <span type="species:ncbi:9606">patients</span>
###xml 2027 2035 <span type="species:ncbi:9606">patients</span>
###xml 2540 2548 <span type="species:ncbi:9606">patients</span>
This in vivo study examined the association between statin treatment and the serum activity of potent matrix remodeling proteases and inflammatory cytokines known to be present in patients suffering from aortic aneurysm. In recent years increasing understanding of the pathogenesis of AAA has generated hope that pharmacotherapy can be applied to patients with small aortic aneurysms (Diehm et al 2007). In vitro and in vivo data have been published that show that HMG CoA reductase inhibitors (statins) may limit AAA growth by inhibitory action on MMP activity in the aortic wall (Schouten et al 2006; Evans et al 2007). Hence statin therapy is now recommended in the conservative management of patients with aortic aneurysms to slow aneurysm growth rate (Golledge et al 2006). Circulating levels of MMPs and OPG are elevated in aneurysm patients, and monitoring of these markers may be helpful in managing these patients and surveying medical treatment. In patients with unstable angina, statin administration reduces circulating levels of inflammatory markers (Tousoulis et al 2006). In patients with aortic aneurysms no data are available on circulating levels of MMPs and other inflammatory cytokines in relation to statin therapy. Hence we analyzed blood samples from patients undergoing elective infrarenal aortic aneurysm repair for the levels of MMP2 and MMP9, OPG, and IL6 and 10 and correlated the data to statin therapy and aneurysm diameter. Surprisingly, statin therapy was not correlated to the circulating levels of the investigated biomarkers. Serum levels in patients on statin therapy were similar to those in patients without statin therapy. Correlation to aneurysm diameter did not reveal significant differences between small, medium-sized, and large aneurysms: patients with small aneurysms, smaller than 5 cm, showed similar activity of MMPs, OPG, and IL10 as did patients with aneurysms larger than 5 cm; however, patients with aneurysms larger than 6 cm showed significantly higher levels of IL6 than patients with smaller aneurysms. This result is in line with those of other investigators who demonstrated that the aortic aneurysm was the source of IL6 and who correlated IL6 levels to aneurysm surface (Dawson et al 2007). Nevertheless, our results partly contradict findings that showed that MMP2 levels were correlated to aneurysm expansion and MMP9 levels to aneurysm rupture (Petersen et al 2002). Other investigators have reported on elevated serum levels of MMP9 in AAA compared with healthy controls and patients with aorto-iliac occlusive disease (McMillan and Pearce 1999; Hovsepian et al 2000). However, in this context several issues are now discussed.
###end p 30
###begin p 31
###xml 426 442 426 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-vhrm-4-1433">Abisi et al 2008</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
First: studies on human blood samples in patients with aortic aneurysm are limited, as patients are usually referred for surgical repair; therefore our measurements are only snapshots in the course of aneurismal expansion and no data on growth rates were available. So the relationship between statin treatment and aneurysm expansion could not be determined - a problem that has already been confirmed by other investigators (Abisi et al 2008). Subsequently the lack of correlation between statin therapy and biomarker activity may not necessarily document a lack of effect of statins on aneurysm growth.
###end p 31
###begin p 32
###xml 258 277 258 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-vhrm-4-1433">Watanabe et al 2006</xref>
###xml 364 384 364 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-4-1433">Hovsepian et al 2000</xref>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
Second: Results are contradictory on the relationship between circulating levels of MMPs and degenerative mechanisms in the wall of aortic aneurysms. On the one hand it has been shown that circulating MMP9 levels fell significantly after aneurysm exclusion (Watanabe et al 2006); on the other hand the negative predictive value of normal MMP9 levels is about 52% (Hovsepian et al 2000). It appears that proteinases from the tissue compartment - the aortic wall - are not released to the plasmatic compartment and therefore MMP levels in the serum of patients do not reflect the situation in the aneurismal wall. Hence further investigations should focus on the correlation between tissue activitiy and serum activitiy in patients with AAA.
###end p 32
###begin p 33
###xml 260 276 260 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-4-1433">Evans et al 2007</xref>
###xml 278 294 278 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-vhrm-4-1433">Abisi et al 2008</xref>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
Third: Most studies on the role of MMPs and other inflammatory markers in aortic aneurysms use healthy volunteers or patients with arterial occlusive disease as control. Only a few investigations have compared patients with aortic aneurysm and statin therapy (Evans et al 2007; Abisi et al 2008).
###end p 33
###begin p 34
###xml 906 923 906 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-vhrm-4-1433">Kertai et al 2004</xref>
###xml 925 942 925 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-vhrm-4-1433">Welten et al 2007</xref>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
###xml 873 881 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
###xml 1233 1241 <span type="species:ncbi:9606">patients</span>
Finally, the power of our investigation was limited (<20%) and the lack of significant correlations may be related to the relatively small number of patients. However, our results, together with published research, suggest that statins may exert an inhibitory effect on proteolytic activity in the aneurismal wall which is not reflected in the serum of aneurysm patients; hence it remains questionable if MMPs and other inflammatory markers such as ILs and OPG can serve as biomarkers in aneurismal disease. In addition the precise mechanisms of statin therapy in the conservative treatment of aortic aneurysm have yet to be examined. To elucidate the role of statins on aneurysm growth long-term follow up in clinical trials would be necessary. However, statins have been documented to be associated with reduced cerebro-cardio-vascular mortality in vascular patients and patients undergoing AAA surgery (Kertai et al 2004; Welten et al 2007). Consequently most vascular patients are on statin treatment and such a clinical trial would prove ethically impossible. Nevertheless, further investigations on the mechanisms of aneurysm growth and effects of pharmacological agents are necessary to develop the best treatment regimen for patients with aortic aneurysms.
###end p 34
###begin p 35
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disclosures</bold>
Disclosures
###end p 35
###begin p 36
The authors have no conflicts of interest to disclose.
###end p 36
###begin title 37
References
###end title 37
###begin article-title 38
Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms
###end article-title 38
###begin article-title 39
Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms
###end article-title 39
###begin article-title 40
Aortic aneurysms secrete interleukin-6 into the circulation
###end article-title 40
###begin article-title 41
Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts
###end article-title 41
###begin article-title 42
Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue
###end article-title 42
###begin article-title 43
Abdominal aortic aneurysm: pathogenesis and implications for management
###end article-title 43
###begin article-title 44
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease
###end article-title 44
###begin article-title 45
Simvastatin suppresses experimental aortic aneurysm expansion
###end article-title 45
###begin article-title 46
###xml 170 178 <span type="species:ncbi:9606">patients</span>
A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery
###end article-title 46
###begin article-title 47
The plasma level of matrix metal-loproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study
###end article-title 47
###begin article-title 48
Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms
###end article-title 48
###begin article-title 49
###xml 36 41 <span type="species:ncbi:9606">human</span>
Association of osteoprotegerin with human abdominal aortic aneurysm progression
###end article-title 49
###begin article-title 50
Proteolysis of the abdominal aortic aneurysm wall and the association with rupture
###end article-title 50
###begin article-title 51
Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth
###end article-title 51
###begin article-title 52
Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta
###end article-title 52
###begin article-title 53
###xml 98 106 <span type="species:ncbi:9606">patients</span>
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level
###end article-title 53
###begin article-title 54
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration
###end article-title 54
###begin article-title 55
###xml 64 72 <span type="species:ncbi:9606">patients</span>
The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair
###end article-title 55
###begin article-title 56
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment
###end article-title 56
###begin p 57
Serum activity of MMP9 according to statin use; median values were 38 and 37 ng/mL, respectively (p = 0.868).
###end p 57
###begin p 58
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: MMP, metalloproteinase.
###end p 58
###begin p 59
Serum activity of MMP2 according to statin use; median values were 209 and 211 ng/mL, respectively (p = 0.394).
###end p 59
###begin p 60
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: MMP, metalloproteinase.
###end p 60
###begin p 61
Serum levels of IL10 according to statin use; median values were 6 and 5 pg/mL, respectively (p = 0.679).
###end p 61
###begin p 62
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: IL, interleukin.
###end p 62
###begin p 63
Serum levels of IL6 according to statin use; median values were 5 and 7 pg/mL, respectively (p = 0.085).
###end p 63
###begin p 64
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: IL, interleukin.
###end p 64
###begin p 65
Serum activity of OPG according to statin use; median values did not differ significantly: 417 vs 430 pg/mL, respectively (p = 0.369).
###end p 65
###begin p 66
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: OPG, osteoprotegerin.
###end p 66
###begin p 67
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Demographic data of 63 patients undergoing elective aneurysm repair according to statin use
###end p 67
###begin p 68
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: Values of age and AAA diameter are given as median and range; other values are expressed as absolute numbers and percentages.
###end p 68
###begin p 69
Mann-Whitney U - test;
###end p 69
###begin p 70
Fisher's exact test.
###end p 70
###begin p 71
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: AAA, abdominal aortic aneurysm.
###end p 71
###begin p 72
Correlation of biomarker activity and aneurysm diameter
###end p 72
###begin p 73
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: Values are given as median and range.
###end p 73
###begin p 74
Kruskal-Wallis one way analysis of variance on ranks;
###end p 74
###begin p 75
significant compared with small (<5 cm) and medium-sized (5.1-6 cm) aneurysms
###end p 75
###begin p 76
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: AAA, abdominal aortic aneurysm; IL, interleukin; MMP, metalloproteinase; OPG, osteoprotegerin.
###end p 76

